Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TSHB

TSHB

Basics

Aliases:
This biomarker is also known as:
  • CHNG4,
  • thyrotropin subunit beta,
  • INN=Thyrotropin alfa,
  • TSH-BETA,
  • Thyrotropin beta chain,
  • TSH,
  • TSH-beta,
  • TSH-B,
  • Thyroid-stimulating hormone subunit beta,
  • thyroid stimulating hormone, beta,
  • thyrotropin beta subunit,
  • Thyrotropin alfa,

View in BioMuta

Description…

TSH, a secreted protein belonging to the glycoprotein hormones subunit beta family, is essential for the control of thyroid structure and metabolism. The four human glycoprotein hormones - chorionic gonadotropin (CG), luteinizing hormone (LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone (TSH)- are dimers consisting of alpha and beta subunits that are associated noncovalently. The alpha subunits of these hormones are identical, however, their beta chains are unique and confer biological specificity. Congenital hypothyroidism is caused by mutation in the TSH gene.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: TSHB

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Curated

Overview

TSHB alone was not shown to be a strong predictor of ovarian cancer.

Performance Comment

Of the ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. TSHB alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

No associated publications found.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.